JP2009541292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541292A5 JP2009541292A5 JP2009515962A JP2009515962A JP2009541292A5 JP 2009541292 A5 JP2009541292 A5 JP 2009541292A5 JP 2009515962 A JP2009515962 A JP 2009515962A JP 2009515962 A JP2009515962 A JP 2009515962A JP 2009541292 A5 JP2009541292 A5 JP 2009541292A5
- Authority
- JP
- Japan
- Prior art keywords
- organic solvent
- solution
- duloxetine
- duloxetine hydrochloride
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 27
- 239000003960 organic solvent Substances 0.000 claims 24
- 229960002496 duloxetine hydrochloride Drugs 0.000 claims 17
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 claims 17
- 239000000243 solution Substances 0.000 claims 15
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 9
- 229960002866 duloxetine Drugs 0.000 claims 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
- 239000012044 organic layer Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 2
- -1 C 6 hydrocarbon Chemical class 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0612506.6A GB0612506D0 (en) | 2006-06-23 | 2006-06-23 | Crystalline duloxetine hydrochloride |
| PCT/GB2007/002325 WO2007148103A1 (en) | 2006-06-23 | 2007-06-21 | Crystalline duloxetine hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541292A JP2009541292A (ja) | 2009-11-26 |
| JP2009541292A5 true JP2009541292A5 (enExample) | 2010-05-13 |
Family
ID=36803801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515962A Pending JP2009541292A (ja) | 2006-06-23 | 2007-06-21 | 結晶塩酸デュロキセチン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7799935B2 (enExample) |
| EP (1) | EP2035404A1 (enExample) |
| JP (1) | JP2009541292A (enExample) |
| CN (1) | CN101627026A (enExample) |
| AU (1) | AU2007262801B2 (enExample) |
| BR (1) | BRPI0711954A2 (enExample) |
| CA (1) | CA2656035A1 (enExample) |
| GB (1) | GB0612506D0 (enExample) |
| NZ (1) | NZ573212A (enExample) |
| WO (1) | WO2007148103A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0612506D0 (en) | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
| EP2107057A1 (en) * | 2008-04-04 | 2009-10-07 | Ranbaxy Laboratories Limited | Process for the preparation of pure duloxetine hydrochloride |
| US20120095239A1 (en) | 2009-03-13 | 2012-04-19 | Alembic Pharmaceuticals Limited | A process for the preparation of duloxetine hydrochloride |
| CN103626735A (zh) * | 2012-08-28 | 2014-03-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸度洛西汀晶型及其制备方法 |
| CN106265528A (zh) * | 2015-05-12 | 2017-01-04 | 法德生技药品股份有限公司 | 制备药物凝集体的方法 |
| JP2016222628A (ja) * | 2015-06-03 | 2016-12-28 | 株式会社トクヤマ | デュロキセチン塩酸塩の製造方法 |
| CN113603673B (zh) * | 2020-11-16 | 2024-08-06 | 上海中西三维药业有限公司 | 一种盐酸度洛西汀的晶型、其制备方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956388A (en) * | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5362886A (en) * | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
| WO2005019199A1 (en) | 2003-08-25 | 2005-03-03 | Hetero Drugs Limited | Amorphous duloxetine hydrochloride |
| US20050197503A1 (en) * | 2004-03-05 | 2005-09-08 | Boehringer Ingelheim International Gmbh | Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| EP1812428A2 (en) | 2004-11-19 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Zolmitriptan crystal forms |
| WO2006058121A1 (en) | 2004-11-23 | 2006-06-01 | Bristol-Myers Squibb Company | Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel |
| JP2007523213A (ja) * | 2004-12-23 | 2007-08-16 | テバ ファーマシューティカル インダストリーズ リミティド | 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法 |
| EP1776049A2 (en) * | 2005-01-27 | 2007-04-25 | Teva Pharmaceutical Industries Ltd. | Duloxetine hcl polymorphs |
| EP1820800A1 (en) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Crystalline forms of duloxetine hydrochloride and processes for their preparation |
| GB0612506D0 (en) | 2006-06-23 | 2006-08-02 | Arrow Int Ltd | Crystalline duloxetine hydrochloride |
-
2006
- 2006-06-23 GB GBGB0612506.6A patent/GB0612506D0/en not_active Ceased
-
2007
- 2007-06-21 JP JP2009515962A patent/JP2009541292A/ja active Pending
- 2007-06-21 EP EP07733321A patent/EP2035404A1/en not_active Withdrawn
- 2007-06-21 CN CN200780023171A patent/CN101627026A/zh active Pending
- 2007-06-21 CA CA002656035A patent/CA2656035A1/en not_active Abandoned
- 2007-06-21 NZ NZ573212A patent/NZ573212A/en not_active IP Right Cessation
- 2007-06-21 AU AU2007262801A patent/AU2007262801B2/en not_active Ceased
- 2007-06-21 WO PCT/GB2007/002325 patent/WO2007148103A1/en not_active Ceased
- 2007-06-21 BR BRPI0711954-2A patent/BRPI0711954A2/pt not_active IP Right Cessation
- 2007-06-22 US US11/821,278 patent/US7799935B2/en not_active Expired - Fee Related
-
2010
- 2010-09-10 US US12/879,616 patent/US8093407B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541292A5 (enExample) | ||
| CN101573368B (zh) | 结晶型1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯半水合物 | |
| JP2009541290A5 (enExample) | ||
| CN101993406B (zh) | 光学活性的吲哚啉化合物及其制备方法 | |
| JPH04226948A (ja) | １−アリール−３−アミノプロパン−１−オール類のキラル合成 | |
| JP2005503386A5 (enExample) | ||
| JP2009541291A5 (enExample) | ||
| TW201906826A (zh) | 奧美卡替莫卡必爾的合成 | |
| JP5247687B2 (ja) | 結晶塩酸デュロキセチン | |
| CN102127092A (zh) | 依维莫斯的制备 | |
| CN101121720B (zh) | 硫酸氢氯吡格雷的制备方法 | |
| CN102395591B (zh) | 一种合成普拉格雷的方法 | |
| JP2009541292A (ja) | 結晶塩酸デュロキセチン | |
| JP2009541291A (ja) | 結晶塩酸デュロキセチン | |
| CN108947989B (zh) | 氘代光学异构体及其医药用途 | |
| CN114008023B (zh) | 索吡溴铵的晶型及其制备方法 | |
| EP2385046B1 (fr) | Phase précurseur et son utilisation pour préparer le sel de magnésium tétrahydraté d'un énantiomère d'oméprazole | |
| CN103965197B (zh) | 别嘌醇晶体制备 | |
| CN111943862A (zh) | 一种抗心衰新药Entresto关键成分沙库巴曲的制备方法 | |
| CN103360365A (zh) | 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺 | |
| CN114751818A (zh) | 一种壬二酸alpha晶型的制备方法 | |
| WO2013075669A1 (zh) | 盐酸达泊西汀的晶体、无定形物及其制备方法 | |
| JP2010518145A5 (enExample) | ||
| WO2022062401A1 (zh) | 一种泰格列净的制备方法 | |
| CN103242294A (zh) | 一种(s)-泮托拉唑钠二水合物及其制备方法 |